Expert Insights

Faith E. Davies, MD, provides an update on treatment options for patients with multiple myeloma in early relapse at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.

Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.

Pinkal Desai, MD, provides the latest updates on clonal hematopoiesis, highlighting what doctors should know about these aging-associated mutations.

Sebastian Stintzing, MD, shares results from the phase 3 FIRE-4 trial showing the administration of an initial cycle of chemotherapy had no effect on the efficacy of first-line FOLFIRI plus cetuximab therapy for patients with RAS wild-type...

Zev Wainberg, MD, reviews results from the NAPOLI-3 study, the first study since 2010 to show an overall survival advantage in pancreatic cancer.

Ajai Chari, MD, provides insight into the FDA approval of teclistamab for relapsed/refractory multiple myeloma and background on the data that led to this approval.

Emma Searle, MD, discusses treatment with teclistamab combined with subcutaneous daratumumab and lenalidomide for patients with multiple myeloma.

Shaji K. Kumar, MD, discusses the PFS and OS benefit seen with daratumumab added to lenalidomide and dexamethasone vs lenalidomide and dexamethasone alone in transplant-ineligible patients with newly diagnosed multiple myeloma.

Kevin H.M. Kuo, MD, discusses the use of mitapivat to improve erythropoiesis in patients with alpha- or beta-non-transfusion-dependent thalassemia.

Stacey Cohen, MD, reviews results from a study evaluating the optimal timing to test for circulating tumor DNA to detect MRD following surgery in patients with colorectal cancer.